Vivet, Therapeutics

Vivet Therapeutics Presents Interim Data from its Phase 1/ 2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

Vivet Therapeutics United Kingdom United States of America France Italy

View original content:https://www.prnewswire.co.uk/news-releases/vivet-therapeutics-presents-interim-data-from-its-phase-12-gateway-trial-for-the-treatment-of-wilson-disease-at-easl-congress-2024-302164669.html

en | boerse | 67981684 |